During the past decade there has been a marked decline in the number of novel drugs developed and approved for treatment of schizophrenia despite a significant investment in research and development by the pharmaceutical industry. The goal of this conference is to facilitate the translation of discoveries in basic neuroscience into the development of innovative pharmacological agents for the treatment of schizophrenia by convening and encouraging dialogue among clinical, translational and basic neuroscientists. Plenary sessions will include discussion of genetic and epigenetic approaches to studying schizophrenia; new molecular targets and approaches to small molecule therapeutics; and the relationship between genes, function, and clinical symptoms.
Conference Art Credit
Sheila L. Lawton
8.5 x 11 in.
For sale by artist
About the Artist
Sheila Lynn Lawton, born July 7, 1957 lives and work in San Diego, CA. S. Lawton describes her work as "steady recklessness with a keen sense of balance." Many times the art is referred to as Picasso-like, the line drawings are often one continuous line. See more of Lawton's art at: sheilalawton.blogspot.com or www.sheshez.com
The project described is supported by Award Number R13MH085413 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health.